Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lexeo Therapeutics, Inc.

NASDAQ: LXEO · Life Sciences · 4 alerts · CIK 1907108

Share price
$3.23Close, Nov 16
Market cap
$267M
Shares outstanding
82.79MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lexeo Therapeutics, Inc. filings on SEC EDGAR ↗

7:06 AM ET 10-Q
Financial Results

Lexeo Therapeutics Q3 2026 Results: Net Loss of $38.3M, Loss Widens

Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.

Key figure
Net loss $38.3M
7:03 AM ET 8-K
Clinical Trial Data

Lexeo Therapeutics Clinical Trial Data

Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.

“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.